免疫检查点抑制剂相关心肌炎的磁共振T1与T2映射评估
本研究基于国际注册的136例免疫检查点抑制剂相关心肌炎患者,其中86例有T1映射、79例有T2映射,评估其诊断与预后价值。结果显示异常T1和T2分别见于78%和43%的患者,应用改良Lake Louise标准95%符合非缺血性心肌损伤、53%符合心肌水肿;native T1对后续MACE有优秀区分能力(AUC 0.91),且T1 z-score每增加1单位与MACE独立相关(HR 1.44)。
要点
- ICI心肌炎患者中异常T1映射常见(78%),T2异常占43%。
- 改良Lake Louise标准诊断非缺血性心肌损伤的符合率达95%。
- Native T1对后续MACE有优秀区分能力(AUC 0.91)且独立相关。
核心结论
- T1映射及改良Lake Louise标准在ICI心肌炎中具有重要诊断价值,T1映射提供预后价值。
研究设计与样本
- 回顾性研究,来自ICI心肌炎国际注册数据库,共136例有CMR的患者,其中86例(63%)有T1映射、79例(58%)有T2映射。
主要发现
- 86例患者平均年龄66.3±13.1岁,36例(41.9%)左心室射血分数<55%。
- 全体患者T1和T2的z-score均值分别为2.9±1.9(p<0.001)和2.2±2.1(p<0.001)。
- 在Siemens 1.5-T扫描仪(n=67)上,native T1为1,079.0±55.5 ms vs. 参考值1,000.3±22.1 ms(p<0.001),T2为56.2±4.9 ms vs. 参考值49.8±2.2 ms(p<0.001)。
- 异常T1和T2分别见于78%和43%的患者;改良Lake Louise标准中95%符合非缺血性心肌损伤标准、53%符合心肌水肿标准。
- Native T1对后续MACE的AUC为0.91(95%CI:0.84–0.98);T1 z-score每增加1单位,HR为1.44(95%CI:1.12–1.84;p=0.004),T2与MACE无独立关联。
关键数值与推荐
- 异常T1和T2定义为高于站点(vendor/field strength specific)参考值2个标准差,并计算每位患者的z-score。
- MACE定义为心血管死亡、心源性休克、心脏骤停和完全性心脏传导阻滞的复合终点。
- 改良Lake Louise标准:95%患者符合非缺血性心肌损伤标准,53%符合心肌水肿标准。
临床怎么用
- 对ICI心肌炎患者可考虑使用CMR T1映射辅助诊断,并应用改良Lake Louise标准评估心肌损伤和水肿。
- Native T1 z-score升高与后续MACE风险独立相关,可用于风险分层。
局限性
- 回顾性研究设计。
- 仅部分患者(86/136有T1、79/136有T2)具备映射数据。
- 异常值定义依赖站点特异性参考值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Myocarditis is a potentially fatal complication of immune checkpoint inhibitor (ICI) therapy. Data on the utility of cardiovascular magnetic resonance (CMR) T1 and T2 mapping in ICI myocarditis are limited. OBJECTIVES: This study sought to assess the value of CMR T1 and T2 mapping in patients with ICI myocarditis. METHODS: In this retrospective study from an international registry of patients with ICI myocarditis, clinical and CMR findings (including T1 and T2 maps) were collected. Abnormal T1 and T2 were defined as 2 SD above site (vendor/field strength specific) reference values and a z-score was calculated for each patient. Major adverse cardiovascular events (MACE) were a composite of cardiovascular death, cardiogenic shock, cardiac arrest, and complete heart block. RESULTS: Of 136 patients with ICI myocarditis with a CMR, 86 (63%) had T1 maps and 79 (58%) also had T2 maps. Among the 86 patients (66.3 ± 13.1 years of age), 36 (41.9%) had a left ventricular ejection fraction <55%. Across all patients, mean z-scores for T1 and T2 values were 2.9 ± 1.9 (p < 0.001) and 2.2 ± 2.1 (p < 0.001), respectively. On Siemens 1.5-T scanner (n = 67), native T1 (1,079.0 ± 55.5 ms vs. 1,000.3 ± 22.1 ms; p < 0.001) and T2 (56.2 ± 4.9 ms vs. 49.8 ± 2.2 ms; p < 0.001) values were elevated compared with reference values. Abnormal T1 and T2 values were seen in 78% and 43% of the patients, respectively. Applying the modified Lake Louise Criteria, 95% met the nonischemic myocardial injury criteria and 53% met the myocardial edema criteria. Native T1 values had excellent discriminatory value for subsequent MACE, with an area under the curve of 0.91 (95% confidence interval: 0.84 to 0.98). Native T1 values (for every 1-unit increase in z-score, hazard ratio: 1.44; 95% confidence interval: 1.12 to 1.84; p = 0.004) but not T2 values were independently associated with subsequent MACE. CONCLUSIONS: The use of T1 mapping and application of the modified Lake Louise Criteria provides important diagnostic value, and T1 mapping provides prognostic value in patients with ICI myocarditis.
引用
- Thavendiranathan P, Zhang L, Zafar A, et al. Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis. J Am Coll Cardiol. 2021. PMID: 33766256. doi:10.1016/j.jacc.2021.01.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。